VistaGen Staggered By Latest Clinical Setback, This Time In Social Anxiety

 
• By Joseph Haas

Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.

Public speaking anxiety
VistaGen tested its SAD candidate in a public speaking model • Source: Shutterstock

More from Clinical Trials

More from R&D